Fortune February 1, 2024
Katrina Compoli, Bloomberg

WW International Inc. suffered its worst month on record in January, erasing the wellness company’s advance since it said in March that it was entering the growing market for a new class of weight-loss drugs.

WW, better known as WeightWatchers, slumped 6.1% on Wednesday, bringing its decline for the month to 57% amid emerging competition and concern around subscriber growth. The latest drop came as part of a broad market slide Wednesday after Federal Reserve Chair Jerome Powell signaled officials aren’t rushing to cut interest rates.

The performance is a stark reversal from 2023. The stock notched its biggest one-day gain since 2015 on March 7 after WW struck a deal for telehealth obesity-drug provider Sequence. Enthusiasm around the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Provider, Wellness
Gen X Less Interested in Trendy Wellness, More Stressed Than Boomers
American Medical Association suggests realistic health goals in 2025
Study: Why Quick Fixes Don’t Work in Workplace Wellness
Will the Trump Administration Be a Dangerous Ally to the Wellness Industry?
B2B Wearables: A New Tool for Businesses to Promote Workplace Wellness

Share This Article